Baseline BMD, anti-TNFα treatment, and disease activity markers were predictive of BMD loss and subsequent osteoporotic fractures in patients with spondyloarthropathies, highlighting the need for regular follow-up to monitor these parameters and adjust treatment accordingly [69]. This evidence concerns the gene TNF and spondyloarthropathy.